Actively Recruiting
Master Protocol Studying Once-Weekly Eloralintide Injections for Adults With Knee Osteoarthritis and Overweight or Obesity
Led by Eli Lilly and Company · Updated on 2026-11-04
900
Participants Needed
147
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of Eloralintide LY3841136 for adults with osteoarthritis of the knee who are overweight or obese and experiencing knee pain. This Phase 3, randomized, double-blind, placebo-controlled study aims to assess how well Eloralintide works in reducing body weight and improving knee pain. The trial is sponsored by Eli Lilly and Company and includes two independent studies under a master protocol. Participants will receive once-weekly subcutaneous injections of either Eloralintide or placebo. The study includes parallel treatment arms comparing Eloralintide to placebo in adults with osteoarthritis knee pain and weight concerns. Treatment lasts for approximately 64 weeks, with dosing and assessments occurring regularly. The study also allows for a total participation duration of about 75 weeks, including screening. During the trial, participants will undergo various assessments including measurements of body weight, knee pain using the Western Ontario and McMaster Universities Osteoarthritis Index WOMAC pain subscale, physical function, blood pressure, inflammatory markers, and walking distance. Researchers will monitor medication use and collect data on quality of life and biochemical markers. Safety and pharmacokinetics of Eloralintide are also tracked throughout the study.
CONDITIONS
Brief Title
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
Research Team
T
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
P
Physicians interested in becoming principal investigators please contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here